To directly assess the effect of current RA therapeutics on IR expression, we examined the impact of TNF Ab, GC, JAKi, and IL-6R Ab using adalimumab, prednisolone, tofacitinib, and tocilizumab, respectively. The gene discussed is IL6R; the disease is rheumatoid arthritis.